dc.contributor.author
Aubets Gil, Eva
dc.contributor.author
Griera Farres, Rosa
dc.contributor.author
Félix, Álex J.
dc.contributor.author
Rigol Pujol, Gemma
dc.contributor.author
Sikorski, Chiara
dc.contributor.author
Limón Magaña, David
dc.contributor.author
Mastrorosa, Chiara
dc.contributor.author
Busquets i Viñas, Ma. Antonia
dc.contributor.author
Pérez García, M. Lluïsa (Maria Lluïsa)
dc.contributor.author
Noé Mata, Verónica
dc.contributor.author
Ciudad i Gómez, Carlos Julián
dc.date.issued
2022-01-12T08:03:45Z
dc.date.issued
2022-12-31T06:10:25Z
dc.date.issued
2022-01-12T08:03:45Z
dc.identifier
https://hdl.handle.net/2445/182280
dc.description.abstract
Nucleic acids therapeutics provide a selective and promising alternative to traditional treatments for multiple genetic diseases. A major obstacle is the development of safe and efficient delivery systems. Here, we report the synthesis of the new cationic gemini amphiphile 1,3-bis[(4-oleyl-1-pyridinio)methyl]benzene dibromide (DOPY). Its transfection efficiency was evaluated using PolyPurine Reverse Hoogsteen hairpins (PPRHs), a nucleic acid tool for gene silencing and gene repair developed in our laboratory. The interaction of DOPY with PPRHs was confirmed by gel retardation assays, and it forms complexes of 155 nm. We also demonstrated the prominent internalization of PPRHs using DOPY compared to other chemical vehicles in SH-SY5Y, PC-3 and DF42 cells. Regarding gene silencing, a specific PPRH against the survivin gene delivered with DOPY decreased survivin protein levels and cell viability more effectively than with N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) in both SH-SY5Y and PC-3 cells. We also validated the applicability of DOPY in gene repair approaches by correcting a point mutation in the endogenous locus of the dhfr gene in DF42 cells using repair-PPRHs. All these results indicate both an efficient entry and release of PPRHs at the intracellular level. Therefore, DOPY can be considered as a new lipid-based vehicle for the delivery of therapeutic oligonucleotides.
dc.format
application/pdf
dc.publisher
Elsevier B.V.
dc.relation
Reproducció del document publicat a: https://doi.org/10.1016/j.ejpb.2021.05.016
dc.relation
European Journal of Pharmaceutics and Biopharmaceutics, 2021, vol. 165, p. 279-292
dc.relation
https://doi.org/10.1016/j.ejpb.2021.05.016
dc.rights
cc-by (c) Eva Aubets Gil, et al, 2021
dc.rights
http://creativecommons.org/licenses/by/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject
Teràpia genètica
dc.subject
Expressió gènica
dc.subject
Gene expression
dc.title
Synthesis and validation of DOPY: A new gemini dioleylbispyridinium based amphiphile for nucleic acid transfection
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion